He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
This product will be manufactured at Lupin’s Nagpur facility in India
US Generics grew 5% to Rs. 467 Crores for the quarter
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
We now rank 3rd in pharmaceutical production by volume and 14th by value
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Subscribe To Our Newsletter & Stay Updated
